



NEUROWAVE MEDICAL TECHNOLOGIES™ LAUNCHES NOMETEX™. A UNIQUE NEUROMODULATION DEVICE TO TREAT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

New, Drug Free Solution Gains Strong Professional Acceptance at American Society of Clinical Oncology Meeting

Chicago, IL – July 7, 2011. Neurowave Medical Technologies™ (NMT) introduced Nometex™, a new transdermal neuromodulation device to treat patients with chemotherapy-induced nausea and vomiting (CINV), at the 2011 scientific meeting of the American Society of Clinical Oncology (ASCO).

Nometex was designed to improve the quality of life for the more than 1.2 million Americans who undergo chemotherapy-radiation treatments each year. Its innovative approach to delivering continuous protection against CINV -- one of most feared side effects of chemotherapy -- garnered enthusiastic professional response at ASCO. Renowned oncologists recognized the clinical efficacy of the drug-free solution, along with its potential to reduce morbidity and cost of therapy.

In a clinical study to test the efficacy of Nometex in gynecologic oncology patients, results showed a significant reduction in the severity of nausea over days 2-4. Further, 92% of active patients using Nometex stated they would recommend the device to others undergoing chemotherapy.

“Nometex is the first medical device cleared by the FDA to treat acute and delayed nausea and vomiting due to

chemotherapy,” said Chris Littel, Vice President of Marketing for Neurowave Medical Technologies. “For years, patients have had to take multiple drugs to treat this debilitating condition, all of which have side effects. Nometex represents a new therapeutic direction that puts patients in control of managing acute and delayed CINV syndromes through 2-3 cycles of chemotherapy. We are pleased to provide an advanced technology that improves the quality of life for patients who are battling cancer.”

Nometex is a non-drug treatment that relies on NMT’s proprietary neuromodulation technology platform to positively modulate neural pathways using electrical pulses for prophylaxis, breakthrough, or refractory CINV. Offering patients a rapid onset of action, usually within minutes, it has been clinically proven to reduce CINV without the side effects associated with pharmaceuticals. The first model Nometex N2C will provide up to 150 hours of therapy, which can help most patients through two cycles of therapy and the associated CINV episodes.

NMT released Nometex N2C earlier this month, and will be expanding its commercial operations to provide support to over 1,700 Oncology clinics located in the U.S.

NEUROWAVE

M E D I C A L T E C H N O L O G I E S



About Neurowave Medical Technologies

Neurowave Medical Technologies™ (NMT) is a rapidly growing, privately held Chicago-based medical device company that develops and commercializes advanced transdermal neuromodulation devices for the prevention and treatment of acute and chronic clinical conditions. Using its patented and proprietary neuromodulation technology platform, NMT's mission is to prevent or eliminate patients' suffering with innovative, non-invasive neuromodulation products across a broad range of conditions. NMT commercializes products via an internal sales force, out-licensing and distribution to various marketing partners worldwide.

For company information, visit www.neurowavemedical.com.

For product information, visit www.nometex.com

Media Contact:

Nadine Tosk, NDT Communications for Neurowave Medical Technologies

847.920.9858;

nadinepr@gmail.com

Or

Imran Hussain, Marketing Manager

312.334.2516;

imran.h@neurowavemedical.com

1 Pearl ML, Fischer M, McCauley DL et al. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. *Cancer Nurs* 1999; 22(4):307-11.